首页 / 院系成果 / 成果详情页

Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis 期刊论文

编号：

897949d0-1ff1-4a75-a969-1fec0ed3a817
作者：

Wang, Li(王丽)#^[1,3]Xia, Yaoxiong(夏耀雄)#^[1,3]Liu, Dequan(刘德权)#^[2]Zeng, Yueqin(曾跃勤)^[2]Chang, Li(常莉)^[1,3]Li, Lan(李岚)^[1,3]Hou, Yu(侯宇)^[1,3]Ge, Lv^[3];Li, Wenhui(李文辉)*^[1,3]Liu, Zhijie*^[2]
语种：

英文
期刊：

ONCOTARGET ISSN：1949-2553 2017 年 8 卷 45 期 (79257 - 79269) ; OCT 3
收录：
关键词：

ductal carcinoma in situ radiotherapy tamoxifen anastrozole network-meta-analysis
摘要：

Objective: Post-surgery adjuvant therapies are very important for patients suffering from ductal carcinoma in situ (DCIS). In this study we conducted a network meta-analysis (NMA) to evaluate the efficacy of different post-surgery adjuvant therapies including tamoxifen, anastrozole and radiation therapy (RT) and their combinations (RT+tamoxifen and RT+anastrozole).
Methods: We searched several databases, including Embase, MEDLINE/PUBMED, Cochrane Library, and Science Citation Index, for relevant studies. We then extracted the data from eligible studies in order to perform our NMA. We measured the comparative efficacy of each treatment option based on the calculated odds ratios (ORs) and the corresponding 95% credibility interval (95% CrI) for each treatment option. We calculated the surfaces under the cumulative ranking curves (SUCRA) in order to rank the therapies according to their different outcomes
Results: In this study, local recurrence (LC) was chosen as the primary outcome. Metastasis, contralateral-breast cancer (CBC), ipsilateral-breast cancer (IBC) and death were secondary outcomes. Patients treated with RT and RT + tamoxifen exhibited a lower risk of LC compared with control group (OR=0.54, 95% CrI: 0.400.73; OR= 0.41, 95% CrI: 0.19-0.90). Patients treated by RT and RT + tamoxifen also exhibited a significantly lower risk of IBC compared with control group (OR=0.55, 95% CrI: 0.37-0.82; OR=0.42, 95% CrI: 0.18-0.99). Results from the SUCRA indicated that RT + anastrozole and RT + tamoxifen were potentially the best adjuvant treatments for patients with DCIS.
Conclusions: In conclusion, the RT + anastrozole and RT + tamoxifen are recommended for their performance and effectiveness.
推荐引用方式
GB/T 7714：

Wang Li,Xia Yaoxiong,Liu Dequan, et al. Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis [J].ONCOTARGET,2017,8(45):79257-79269.
APA：

Wang Li,Xia Yaoxiong,Liu Dequan,Zeng Yueqin,&Liu Zhijie.(2017).Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis .ONCOTARGET,8(45):79257-79269.
MLA：

Wang Li, et al. "Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis" .ONCOTARGET 8,45(2017):79257-79269.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：345  下载次数：0

分享到：

浏览次数：345

下载次数：0

打印次数：0